ArticlePloS one2026
The impact of cognitive impairment and low muscle mass on all-cause mortality among older adults in China: An empirical analysis based on CLHLS cohort data.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCognitive impairment and low muscle mass are prevalent conditions in later life, and each has been independently associated with adverse health outcomes. Both conditions are heterogeneous and may arise from multiple underlying etiologies. However, evidence regarding their combined association with all-cause mortality remains limited, particularly among older adults in China. Therefore, this study aimed to investigate the independent and joint associations of cognitive impairment and low muscle mass with all-cause mortality using data from a large prospective cohort.
methodsData from the China Longitudinal Healthy Longevity Survey (CLHLS) collected between 2011 and 2018 were analyzed. Kaplan-Meier survival analyses and log-rank tests were conducted, and Cox proportional hazards models were applied to estimate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for all-cause mortality. Subgroup and sensitivity analyses were additionally performed to evaluate the robustness of the findings.
resultsA total of 5,625 participants were included and classified into four groups: neither cognitive impairment (CI) nor low muscle mass (LMM) (CI - /LMM - , n = 1,698; 30.2%), low muscle mass only (CI - /LMM + , n = 2,795; 49.7%), cognitive impairment only (CI + /LMM - , n = 341; 6.1%), and both cognitive impairment and low muscle mass (CI + /LMM + , n = 791; 14.1%). Kaplan-Meier survival analyses and multivariable Cox proportional hazards models demonstrated that participants in the CI + /LMM+ group had the highest risk of all-cause mortality (p < 0.001). Compared with the CI - /LMM- group, the adjusted hazard ratios (HRs) were 1.29 (95% CI: 1.01-1.51) for the CI - /LMM+ group, 1.92 (95% CI: 1.50-2.45) for the CI + /LMM- group, and 2.54 (95% CI: 2.11-3.05) for the CI + /LMM+ group. Sensitivity analyses confirmed the robustness of the main findings, revealing a significant increasing trend in mortality risk across the four groups (trend p < 0.001). In subgroup analyses, the CI + /LMM+ group was significantly associated with an elevated risk of all-cause mortality among women and participants aged <80 years.
conclusionsThe coexistence of cognitive impairment and low muscle mass was associated with a substantially increased risk of all-cause mortality, particularly among women and individuals younger than 80 years. The concurrent presence of these conditions may help identify a subgroup of older adults at heightened risk of adverse outcomes, underscoring the importance of comprehensive geriatric assessment and enhanced clinical surveillance in aging populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.